Jpmorgan Chase & CO Fibrogen Inc Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Fibrogen Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 315,361 shares of FGEN stock, worth $104,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares

315,361

Previous 98,596 219.85%

Holding current value

$104,069

Previous $231,000 21.21%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$0.89 - $2.36 $192,920 - $511,565	216,765 Added 219.85%	315,361 $280,000
Q1 2024 May 10, 2024	BUY	$0.73 - $2.73 $28,079 - $105,009	38,465 Added 63.97%	98,596 $231,000
Q4 2023 Feb 12, 2024	SELL	$0.38 - $0.91 $26,468 - $63,384	-69,653 Reduced 53.67%	60,131 $53,000
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $1,547 - $5,543	-1,959 Reduced 1.49%	129,784 $111,000
Q2 2023 Aug 11, 2023	SELL	$2.49 - $20.59 $91,007 - $752,543	-36,549 Reduced 21.72%	131,743 $355,000
Q1 2023 May 18, 2023	BUY	$15.95 - $25.18 $1.75 Million - $2.76 Million	109,792 Added 187.68%	168,292 $3.14 Million
Q1 2023 May 11, 2023	SELL	$15.95 - $25.18 $1.94 Million - $3.06 Million	-121,554 Reduced 67.51%	58,500 $1.09 Million
Q4 2022 Feb 13, 2023	BUY	$13.27 - $17.73 $506,688 - $676,984	38,183 Added 26.91%	180,054 $2.88 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $8,664 - $11,096	-760 Reduced 0.53%	141,871 $1.85 Million
Q2 2022 Aug 11, 2022	BUY	$7.94 - $12.96 $162,523 - $265,278	20,469 Added 16.76%	142,631 $1.51 Million
Q1 2022 May 11, 2022	SELL	$12.02 - $16.79 $23,174 - $32,371	-1,928 Reduced 1.55%	122,162 $1.47 Million
Q4 2021 Feb 10, 2022	SELL	$9.93 - $15.39 $11.4 Million - $17.7 Million	-1,150,876 Reduced 90.27%	124,090 $1.75 Million
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $13 Million - $34 Million	1,274,966 New	1,274,966 $13 Million

Others Institutions Holding FGEN

# of Institutions

111

Shares Held

58.2M

Call Options Held

2.14M

Put Options Held

907K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $30.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Fibrogen Inc Transaction History